ArticleFrontiers in oncology2026
Case Report: A rare case of esophageal squamous cell carcinoma with metastases to the pancreas and stomach.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal cancer is a highly aggressive malignancy associated with a generally poor clinical prognosis. While distant metastases are common, the metastasis of esophageal squamous cell carcinoma (ESCC) to the pancreas and stomach is extremely rare. We report the case of a 62-year-old male with a history of ESCC who presented with an incidentally discovered pancreatic mass on imaging 37 months after the completion of radiotherapy. The patient subsequently underwent radical surgical resection. Postoperative histopathological and immunohistochemical analyses confirmed the presence of pancreatic and gastric metastases originating from the primary ESCC. For subsequent disease management, the patient received a systemic regimen comprising immune checkpoint inhibitors combined with platinum-based chemotherapy. This case underscores the importance of considering rare metastases in the differential diagnosis of new pancreatic lesions in patients with a history of ESCC, even following a prolonged disease-free interval. Furthermore, it suggests that aggressive surgical resection combined with postoperative immunochemotherapy may represent a viable multidisciplinary therapeutic strategy for managing such atypical metastatic presentations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.